Skip to content

Study of Optimal Posology of Gonadotrophins in Patients With Insufficient Ovarian Response Due to Age

Study of Optimal Posology of Gonadotrophins in Patients With Insufficient Ovarian Response Due to Age

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00575302
Enrollment
400
Registered
2007-12-18
Start date
2007-12-31
Completion date
2009-12-31
Last updated
2010-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

IVF, poor responder, recFSH, Fertilization in Vitro, Poor responders

Brief summary

In In vitro fertilization (IVF) treatment, poor responder patients of more than 38 years old are randomized prospectively into two dosages of gonadotrophins. The outcome of treatment will be analyzed.

Detailed description

Women \> 38 years, who had an insufficient response to stimulation with regular (for age) posology of 225 IU of gonadotrophins (urinary or recombinant), in an agonist protocol will be randomized prospectively into 2 groups: 300 IU versus 450 IU of Gonal-f® administered in a short agonist protocol. Insufficient response is defined as: development of ≤ 4 mature follicles (of ≥ 16 mm) at time of hCG administration. Patient can be eligible for several cycles in same protocol.

Interventions

DRUGGonal-f®: follitropin alpha

Gonal-f®: follitropin alpha, administration of 300 U

Sponsors

EMD Serono
CollaboratorINDUSTRY
Centre Hospitalier Chretien
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
38 Years to 42 Years
Healthy volunteers
No

Inclusion criteria

* Women \> 38 years with insufficient response to stimulation with 225 IU of gonadotrophins (urinary or recombinant), in an agonist protocol. * Insufficient response is defined as: development of ≤ 4 mature follicles (of ≥ 16 mm) at time of hCG administration. * Patient can be eligible for several cycles in same protocol.

Exclusion criteria

* Patients who already received doses \> 225 IU * Patients older than 42 years * Patients with basal FSH concentrations ≥ 15 mU/ml at day 3

Design outcomes

Primary

MeasureTime frame
number of mature oocytes1 month

Secondary

MeasureTime frame
follicular development1 month
fertilization rate1 month
implantation rate1 month
embryo quality1 month
pregnancy rate1 month

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026